Cargando…
Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy
BACKGROUND: This study examined the usefulness of cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels as a candidate biomarker of neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (...
Autores principales: | Katayama, Takayuki, Sawada, Jun, Takahashi, Kae, Yahara, Osamu, Hasebe, Naoyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493707/ https://www.ncbi.nlm.nih.gov/pubmed/34610837 http://dx.doi.org/10.1186/s13195-021-00907-3 |
Ejemplares similares
-
Cerebrospinal Fluid Biomarkers in Parkinson’s Disease: A Critical Overview of the Literature and Meta-Analyses
por: Katayama, Takayuki, et al.
Publicado: (2020) -
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014) -
Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
por: Mukaetova-Ladinska, Elizabeta B., et al.
Publicado: (2010) -
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020) -
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson’s Disease and Lewy Body Dementia
por: Maetzler, Walter, et al.
Publicado: (2016)